Department of Urology and Medical Oncology, Brady Urologic Health Center, Weill Cornell Medical College, 525 East 68th Street, Starr 900, New York, NY 10065, USA.
World J Urol. 2011 Aug;29(4):481-6. doi: 10.1007/s00345-010-0594-7. Epub 2010 Oct 1.
Women have been associated with adverse outcomes after radical cystectomy for lower tract urothelial carcinoma. We evaluated the prognostic value of gender in an international cohort of patients treated with radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC).
We retrospectively studied 754 patients treated with RNU for UTUC without neoadjuvant chemotherapy at nine centers located in Asia, Canada, and Europe. Univariable and multivariable Cox regression analyses were used to address recurrence-free (RFS) and cancer-specific survival (CSS) estimates. Median follow-up was 40 months (interquartile range: 18-75).
The majority of patients was of men (516, 68.4%). Women were older than men at the time of RNU (median: 69.2 vs. 66.5 years; P = 0.0003). Women were less likely to have high-grade disease, undergo lymph node dissection, and to receive adjuvant chemotherapy. Gender was not associated with pathologic stage, lymph node metastasis, lymphovascular invasion, concomitant CIS, tumor architecture, or tumor necrosis. On univariable Cox regression analyses, there was no association between gender and cancer recurrence (P = 0.76) or cancer-specific mortality (P = 0.30). On multivariable Cox regression analyses that adjusted for the effects of clinicopathologic features, gender was not associated with disease recurrence (P = 0.47) or cancer-specific survival (P = 0.15).
We found no difference in histopathologic features and outcomes between men and women treated with RNU for UTUC. Nevertheless, epidemiologic and mechanistic molecular studies should be encouraged to design, analyze, and report gender-specific associations to aid in our understanding of gender impact on UTUC incidence, progression, and metastasis.
女性在接受根治性膀胱切除术治疗下尿路尿路上皮癌后,其预后较差。我们评估了性别在接受根治性肾输尿管切除术(RNU)治疗上尿路尿路上皮癌(UTUC)的国际患者队列中的预后价值。
我们回顾性研究了 9 个中心的 754 例接受 RNU 治疗且未接受新辅助化疗的 UTUC 患者,这些中心分别位于亚洲、加拿大和欧洲。采用单变量和多变量 Cox 回归分析评估无复发生存(RFS)和癌症特异性生存(CSS)估计。中位随访时间为 40 个月(四分位距:18-75)。
大多数患者为男性(516 例,68.4%)。与男性相比,女性在接受 RNU 时年龄更大(中位数:69.2 岁比 66.5 岁;P=0.0003)。女性更有可能患有高级别疾病、接受淋巴结清扫术和辅助化疗。性别与病理分期、淋巴结转移、脉管侵犯、同时存在 CIS、肿瘤结构或肿瘤坏死无关。在单变量 Cox 回归分析中,性别与癌症复发(P=0.76)或癌症特异性死亡率(P=0.30)之间无关联。在多变量 Cox 回归分析中,调整了临床病理特征的影响后,性别与疾病复发(P=0.47)或癌症特异性生存(P=0.15)无关。
我们发现接受 RNU 治疗的 UTUC 男性和女性的组织病理学特征和结局无差异。然而,应鼓励进行流行病学和机制分子研究,以设计、分析和报告性别特异性关联,以帮助我们了解性别对 UTUC 发病率、进展和转移的影响。